Lupus & antiphospholipid syndrome
Real-world use of anifrolumab in systemic lupus erythematosus: A retrospective study from a Danish tertiary center (2022–2025)
Authors' conclusion
Anifrolumab was associated with rapid, sustained disease control and significant steroid-sparing effects.
Study context
- Population
- Systemic lupus erythematosus (SLE)/discoid lupus patients treated with anifrolumab at Aarhus University Hospital, Denmark, May 2022–February 2025 (94% female, mean age 52 years)94% female, mean age 52 years
- Participants
- 36 patients
- Outcome
- Disease activity (SLEDAI-2K, PGA, LLDAS, DORIS)
Methodological detailsobservational, single-centre
- Observational
- Single-centre
Main finding
As reported in the abstract
- Median SLEDAI-2K at baseline
- 8
- Median SLEDAI-2K at month 3
- 2
- Median SLEDAI-2K at month 6 and last follow-up
- 0
- SLEDAI-2K = 0 at baseline
- 0%
- SLEDAI-2K = 0 at 6 months and last follow-up
- 52%
- Physician's Global Assessment (PGA) ≤0.5 and LLDAS at last follow-up
- 87%
- DORIS remission at last follow-up
- 70%
- Prednisolone dose decline
- >50%
Observational data: associations, not effects.
Safety
Herpesvirus-related infections (most frequent AEs)
- Severe cases
- 2
- Treatment was generally continued
Original publication
Real-world use of anifrolumab in systemic lupus erythematosus: A retrospective study from a Danish tertiary center (2022–2025). Lupus. Published 1 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →